Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 199 entries
Sorted by: Best Match Show Resources per page
Acute Low-Dose Hydralazine-Induced Lupus Pneumonitis.

Case reports in pulmonology

Holman SK, Parris D, Meyers S, Ramirez J.
PMID: 28932614
Case Rep Pulmonol. 2017;2017:2650142. doi: 10.1155/2017/2650142. Epub 2017 Aug 08.

A 35-year-old female was started on hydralazine 10 mg orally three times a day for treatment of postpartum hypertension. Three months later, after multiple unsuccessful courses of prednisone and antibiotics for presumed pneumonia and asthma exacerbations, her respiratory symptoms...

Cite
Holman SK, Parris D, Meyers S, et al. Acute Low-Dose Hydralazine-Induced Lupus Pneumonitis. Case Rep Pulmonol. 2017;2017:2650142doi: 10.1155/2017/2650142.
Holman, S. K., Parris, D., Meyers, S., & Ramirez, J. (2017). Acute Low-Dose Hydralazine-Induced Lupus Pneumonitis. Case reports in pulmonology, 20172650142. https://doi.org/10.1155/2017/2650142
Holman, Sarah K, et al. "Acute Low-Dose Hydralazine-Induced Lupus Pneumonitis." Case reports in pulmonology vol. 2017 (2017): 2650142. doi: https://doi.org/10.1155/2017/2650142
Holman SK, Parris D, Meyers S, Ramirez J. Acute Low-Dose Hydralazine-Induced Lupus Pneumonitis. Case Rep Pulmonol. 2017;2017:2650142. doi: 10.1155/2017/2650142. Epub 2017 Aug 08. PMID: 28932614; PMCID: PMC5591929.
Copy Download .nbib Format: NLM
Management of hypertensive crises in the elderly.

Journal of geriatric cardiology : JGC

Alshami A, Romero C, Avila A, Varon J.
PMID: 30364798
J Geriatr Cardiol. 2018 Jul;15(7):504-512. doi: 10.11909/j.issn.1671-5411.2018.07.007.

Hypertensive crises are elevations of blood pressure higher than 180/120 mmHg. These can be urgent or emergent, depending on the presence of end organ damage. The clinical presentation of hypertensive crises is quite variable in elderly patients, and clinicians...

Cite
Alshami A, Romero C, Avila A, et al. Management of hypertensive crises in the elderly. J Geriatr Cardiol. 2018;15(7):504-512doi: 10.11909/j.issn.1671-5411.2018.07.007.
Alshami, A., Romero, C., Avila, A., & Varon, J. (2018). Management of hypertensive crises in the elderly. Journal of geriatric cardiology : JGC, 15(7), 504-512. https://doi.org/10.11909/j.issn.1671-5411.2018.07.007
Alshami, Abbas, et al. "Management of hypertensive crises in the elderly." Journal of geriatric cardiology : JGC vol. 15,7 (2018): 504-512. doi: https://doi.org/10.11909/j.issn.1671-5411.2018.07.007
Alshami A, Romero C, Avila A, Varon J. Management of hypertensive crises in the elderly. J Geriatr Cardiol. 2018 Jul;15(7):504-512. doi: 10.11909/j.issn.1671-5411.2018.07.007. PMID: 30364798; PMCID: PMC6198269.
Copy Download .nbib Format: NLM
Hydralazine induces myeloperoxidase and proteinase 3 anti-neutrophil cytoplasmic antibody vasculitis and leads to pulmonary renal syndrome.

Case reports in nephrology

Agarwal G, Sultan G, Werner SL, Hura C.
PMID: 25210633
Case Rep Nephrol. 2014;2014:868590. doi: 10.1155/2014/868590. Epub 2014 Aug 26.

We report a case of hydralazine-induced ANCA-associated glomerulonephritis with pulmonary hemorrhage. A 62-year-old Hispanic man with hypertension, who was being treated with hydralazine 100 mg three times a day for four and half years, presented to the hospital with...

Cite
Agarwal G, Sultan G, Werner SL, et al. Hydralazine induces myeloperoxidase and proteinase 3 anti-neutrophil cytoplasmic antibody vasculitis and leads to pulmonary renal syndrome. Case Rep Nephrol. 2014;2014:868590doi: 10.1155/2014/868590.
Agarwal, G., Sultan, G., Werner, S. L., & Hura, C. (2014). Hydralazine induces myeloperoxidase and proteinase 3 anti-neutrophil cytoplasmic antibody vasculitis and leads to pulmonary renal syndrome. Case reports in nephrology, 2014868590. https://doi.org/10.1155/2014/868590
Agarwal, Gaurav, et al. "Hydralazine induces myeloperoxidase and proteinase 3 anti-neutrophil cytoplasmic antibody vasculitis and leads to pulmonary renal syndrome." Case reports in nephrology vol. 2014 (2014): 868590. doi: https://doi.org/10.1155/2014/868590
Agarwal G, Sultan G, Werner SL, Hura C. Hydralazine induces myeloperoxidase and proteinase 3 anti-neutrophil cytoplasmic antibody vasculitis and leads to pulmonary renal syndrome. Case Rep Nephrol. 2014;2014:868590. doi: 10.1155/2014/868590. Epub 2014 Aug 26. PMID: 25210633; PMCID: PMC4158427.
Copy Download .nbib Format: NLM
Pseudomelanosis intestini "from pylorus to jejunum:" A rare endoscopic finding in a patient with GI bleeding.

Journal of family medicine and primary care

Zakaria A, Abdu B, Al Share B, Manabat M, Ngo K.
PMID: 30598973
J Family Med Prim Care. 2018 Sep-Oct;7(5):1120-1122. doi: 10.4103/jfmpc.jfmpc_53_18.

Pseudomelanosis of the gastrointestinal (GI) tract is a rare condition used to describe the accumulation of pigment deposits in the intestinal mucosa. Its underlying cause is not well understood. It has been described in association with gastrointestinal hemorrhage, chronic...

Cite
Zakaria A, Abdu B, Al Share B, et al. Pseudomelanosis intestini "from pylorus to jejunum:" A rare endoscopic finding in a patient with GI bleeding. J Family Med Prim Care. 2018;7(5):1120-1122doi: 10.4103/jfmpc.jfmpc_53_18.
Zakaria, A., Abdu, B., Al Share, B., Manabat, M., & Ngo, K. (2018). Pseudomelanosis intestini "from pylorus to jejunum:" A rare endoscopic finding in a patient with GI bleeding. Journal of family medicine and primary care, 7(5), 1120-1122. https://doi.org/10.4103/jfmpc.jfmpc_53_18
Zakaria, Ali, et al. "Pseudomelanosis intestini "from pylorus to jejunum:" A rare endoscopic finding in a patient with GI bleeding." Journal of family medicine and primary care vol. 7,5 (2018): 1120-1122. doi: https://doi.org/10.4103/jfmpc.jfmpc_53_18
Zakaria A, Abdu B, Al Share B, Manabat M, Ngo K. Pseudomelanosis intestini "from pylorus to jejunum:" A rare endoscopic finding in a patient with GI bleeding. J Family Med Prim Care. 2018 Sep-Oct;7(5):1120-1122. doi: 10.4103/jfmpc.jfmpc_53_18. PMID: 30598973; PMCID: PMC6259497.
Copy Download .nbib Format: NLM
An intriguing case of anemia and renal failure.

Proceedings (Baylor University. Medical Center)

Baradhi KM.
PMID: 30956590
Proc (Bayl Univ Med Cent). 2019 Jan 24;32(1):78-79. doi: 10.1080/08998280.2018.1540824. eCollection 2019 Jan.

Hydralazine-induced vasculitis is an established autoimmune entity but widely underdiagnosed despite its initial description in 1953. Hydralazine-induced lupus occurs in 5% to 10% of patients and is characterized by fever, arthralgias, rash, anemia, leukopenia, and positive antinuclear antibodies. Renal...

Cite
Baradhi KM. An intriguing case of anemia and renal failure. Proc (Bayl Univ Med Cent). 2019;32(1):78-79doi: 10.1080/08998280.2018.1540824.
Baradhi, K. M. (2019). An intriguing case of anemia and renal failure. Proceedings (Baylor University. Medical Center), 32(1), 78-79. https://doi.org/10.1080/08998280.2018.1540824
Baradhi, Krishna M. "An intriguing case of anemia and renal failure." Proceedings (Baylor University. Medical Center) vol. 32,1 (2019): 78-79. doi: https://doi.org/10.1080/08998280.2018.1540824
Baradhi KM. An intriguing case of anemia and renal failure. Proc (Bayl Univ Med Cent). 2019 Jan 24;32(1):78-79. doi: 10.1080/08998280.2018.1540824. eCollection 2019 Jan. PMID: 30956590; PMCID: PMC6442904.
Copy Download .nbib Format: NLM
Isoniazid-Induced Systemic Lupus Erythematosus: A Case Report.

Drug safety - case reports

Vaghela JH, Solanki Y, Lakhani K, Purohit B.
PMID: 31541371
Drug Saf Case Rep. 2019 Sep 20;6(1):7. doi: 10.1007/s40800-019-0102-y.

Systemic lupus erythematosus (SLE) can be induced by various medications, such as hydralazine, procainamide, isoniazid, methyldopa, chlorpromazine, quinidine, and minocycline. A patient was admitted complaining of fever with chills and rigor. After being diagnosed with tuberculous meningitis, the patient...

Cite
Vaghela JH, Solanki Y, Lakhani K, et al. Isoniazid-Induced Systemic Lupus Erythematosus: A Case Report. Drug Saf Case Rep. 2019;6(1):7doi: 10.1007/s40800-019-0102-y.
Vaghela, J. H., Solanki, Y., Lakhani, K., & Purohit, B. (2019). Isoniazid-Induced Systemic Lupus Erythematosus: A Case Report. Drug safety - case reports, 6(1), 7. https://doi.org/10.1007/s40800-019-0102-y
Vaghela, Jitendra H, et al. "Isoniazid-Induced Systemic Lupus Erythematosus: A Case Report." Drug safety - case reports vol. 6,1 (2019): 7. doi: https://doi.org/10.1007/s40800-019-0102-y
Vaghela JH, Solanki Y, Lakhani K, Purohit B. Isoniazid-Induced Systemic Lupus Erythematosus: A Case Report. Drug Saf Case Rep. 2019 Sep 20;6(1):7. doi: 10.1007/s40800-019-0102-y. PMID: 31541371; PMCID: PMC6754470.
Copy Download .nbib Format: NLM
Naphthoquinone-based Hydrazone Hybrids: Synthesis and Potent Activity Against Cancer Cell Lines.

Medicinal chemistry (Shariqah (United Arab Emirates))

Guimaráes DG, de Assis Gonsalves A, Rolim LA, Araújo EC, Dos Anjos Santos VL, Silva MFS, de Cássia Evangelista de Oliveira F, da Costa MP, Pessoa C, Fonseca Goulart MO, Silva TL, Santos DC, Araújo CRM.
PMID: 32807066
Med Chem. 2021;17(9):945-955. doi: 10.2174/1573406416666200817164308.

BACKGROUND: Natural naphthoquinones have shown diversified biological activities including antibacterial, antifungal, antimalarial, and cytotoxic activities. However, they are also compounds with acute cytotoxicity, immunotoxicity, carcinogenesis, and cardio- and hepatotoxicity, and the modification at their redox center is an interesting...

Cite
Guimaráes DG, de Assis Gonsalves A, Rolim LA, et al. Naphthoquinone-based Hydrazone Hybrids: Synthesis and Potent Activity Against Cancer Cell Lines. Med Chem. 2021;17(9):945-955doi: 10.2174/1573406416666200817164308.
Guimaráes, D. G., de Assis Gonsalves, A., Rolim, L. A., Araújo, E. C., Dos Anjos Santos, V. L., Silva, M. F. S., de Cássia Evangelista de Oliveira, F., da Costa, M. P., Pessoa, C., Fonseca Goulart, M. O., Silva, T. L., Santos, D. C., & Araújo, C. R. M. (2021). Naphthoquinone-based Hydrazone Hybrids: Synthesis and Potent Activity Against Cancer Cell Lines. Medicinal chemistry (Shariqah (United Arab Emirates)), 17(9), 945-955. https://doi.org/10.2174/1573406416666200817164308
Guimaráes, Délis Galváo, et al. "Naphthoquinone-based Hydrazone Hybrids: Synthesis and Potent Activity Against Cancer Cell Lines." Medicinal chemistry (Shariqah (United Arab Emirates)) vol. 17,9 (2021): 945-955. doi: https://doi.org/10.2174/1573406416666200817164308
Guimaráes DG, de Assis Gonsalves A, Rolim LA, Araújo EC, Dos Anjos Santos VL, Silva MFS, de Cássia Evangelista de Oliveira F, da Costa MP, Pessoa C, Fonseca Goulart MO, Silva TL, Santos DC, Araújo CRM. Naphthoquinone-based Hydrazone Hybrids: Synthesis and Potent Activity Against Cancer Cell Lines. Med Chem. 2021;17(9):945-955. doi: 10.2174/1573406416666200817164308. PMID: 32807066.
Copy Download .nbib Format: NLM
Probable Rare Case of Cholecystitis After Exposure to Supratherapeutic Doses of Hydralazine.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Peng A, Reilly T.
PMID: 34860926
J Pharm Technol. 2015 Jun;31(3):135-137. doi: 10.1177/8755122514558124. Epub 2014 Nov 10.

No abstract available.

Cite
Peng A, Reilly T. Probable Rare Case of Cholecystitis After Exposure to Supratherapeutic Doses of Hydralazine. J Pharm Technol. 2014;31(3):135-137doi: 10.1177/8755122514558124.
Peng, A., & Reilly, T. (2015). Probable Rare Case of Cholecystitis After Exposure to Supratherapeutic Doses of Hydralazine. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 31(3), 135-137. https://doi.org/10.1177/8755122514558124
Peng, Alex, and Reilly, Timothy. "Probable Rare Case of Cholecystitis After Exposure to Supratherapeutic Doses of Hydralazine." The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians vol. 31,3 (2015): 135-137. doi: https://doi.org/10.1177/8755122514558124
Peng A, Reilly T. Probable Rare Case of Cholecystitis After Exposure to Supratherapeutic Doses of Hydralazine. J Pharm Technol. 2015 Jun;31(3):135-137. doi: 10.1177/8755122514558124. Epub 2014 Nov 10. PMID: 34860926; PMCID: PMC5990178.
Copy Download .nbib Format: NLM
A hydralazine-induced triumvirate: Lupus, cutaneous vasculitis, and cryptococcoid Sweet syndrome.

JAAD case reports

Skaljic M, Agarwal A, Smith RJ, Nguyen CV, Xu X, Shahane A, Degnan K, Greenblatt J, Rosenbach M.
PMID: 31720352
JAAD Case Rep. 2019 Oct 31;5(11):1006-1009. doi: 10.1016/j.jdcr.2019.08.020. eCollection 2019 Nov.

No abstract available.

Cite
Skaljic M, Agarwal A, Smith RJ, et al. A hydralazine-induced triumvirate: Lupus, cutaneous vasculitis, and cryptococcoid Sweet syndrome. JAAD Case Rep. 2019;5(11):1006-1009doi: 10.1016/j.jdcr.2019.08.020.
Skaljic, M., Agarwal, A., Smith, R. J., Nguyen, C. V., Xu, X., Shahane, A., Degnan, K., Greenblatt, J., & Rosenbach, M. (2019). A hydralazine-induced triumvirate: Lupus, cutaneous vasculitis, and cryptococcoid Sweet syndrome. JAAD case reports, 5(11), 1006-1009. https://doi.org/10.1016/j.jdcr.2019.08.020
Skaljic, Meliha, et al. "A hydralazine-induced triumvirate: Lupus, cutaneous vasculitis, and cryptococcoid Sweet syndrome." JAAD case reports vol. 5,11 (2019): 1006-1009. doi: https://doi.org/10.1016/j.jdcr.2019.08.020
Skaljic M, Agarwal A, Smith RJ, Nguyen CV, Xu X, Shahane A, Degnan K, Greenblatt J, Rosenbach M. A hydralazine-induced triumvirate: Lupus, cutaneous vasculitis, and cryptococcoid Sweet syndrome. JAAD Case Rep. 2019 Oct 31;5(11):1006-1009. doi: 10.1016/j.jdcr.2019.08.020. eCollection 2019 Nov. PMID: 31720352; PMCID: PMC6838470.
Copy Download .nbib Format: NLM
The impact of antihypertensive use in the treatment of acute ischemic stroke in patients receiving alteplase.

The American journal of emergency medicine

Rech MA, Donahey E, DeMott JM, Coles LL, Peksa GD.
PMID: 34329955
Am J Emerg Med. 2021 Dec;50:93-96. doi: 10.1016/j.ajem.2021.07.037. Epub 2021 Jul 22.

BACKGROUND: Treatment of acute ischemic stroke (AIS) with intravenous alteplase within 4.5 h of symptom onset is associated with neurologic improvement. High baseline blood pressure (BP) and BP variability during the first 24 h of AIS is associated with...

Cite
Rech MA, Donahey E, DeMott JM, et al. The impact of antihypertensive use in the treatment of acute ischemic stroke in patients receiving alteplase. Am J Emerg Med. 2021;50:93-96doi: 10.1016/j.ajem.2021.07.037.
Rech, M. A., Donahey, E., DeMott, J. M., Coles, L. L., & Peksa, G. D. (2021). The impact of antihypertensive use in the treatment of acute ischemic stroke in patients receiving alteplase. The American journal of emergency medicine, 5093-96. https://doi.org/10.1016/j.ajem.2021.07.037
Rech, Megan A, et al. "The impact of antihypertensive use in the treatment of acute ischemic stroke in patients receiving alteplase." The American journal of emergency medicine vol. 50 (2021): 93-96. doi: https://doi.org/10.1016/j.ajem.2021.07.037
Rech MA, Donahey E, DeMott JM, Coles LL, Peksa GD. The impact of antihypertensive use in the treatment of acute ischemic stroke in patients receiving alteplase. Am J Emerg Med. 2021 Dec;50:93-96. doi: 10.1016/j.ajem.2021.07.037. Epub 2021 Jul 22. PMID: 34329955.
Copy Download .nbib Format: NLM
Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines.

Pharmaceuticals (Basel, Switzerland)

Pacheco MB, Camilo V, Lopes N, Moreira-Silva F, Correia MP, Henrique R, Jerónimo C.
PMID: 34358096
Pharmaceuticals (Basel). 2021 Jul 13;14(7). doi: 10.3390/ph14070670.

Among the well-established alterations contributing to prostate cancer (PCa) pathogenesis, epigenetics is an important player in its development and aggressive disease state. Moreover, since no curative therapies are available for advanced stage disease, there is an urgent need for...

Cite
Pacheco MB, Camilo V, Lopes N, et al. Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines. Pharmaceuticals (Basel). 2021;14(7)doi: 10.3390/ph14070670.
Pacheco, M. B., Camilo, V., Lopes, N., Moreira-Silva, F., Correia, M. P., Henrique, R., & Jerónimo, C. (2021). Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines. Pharmaceuticals (Basel, Switzerland), 14(7), . https://doi.org/10.3390/ph14070670
Pacheco, Mariana Brütt, et al. "Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines." Pharmaceuticals (Basel, Switzerland) vol. 14,7 (2021). doi: https://doi.org/10.3390/ph14070670
Pacheco MB, Camilo V, Lopes N, Moreira-Silva F, Correia MP, Henrique R, Jerónimo C. Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines. Pharmaceuticals (Basel). 2021 Jul 13;14(7). doi: 10.3390/ph14070670. PMID: 34358096; PMCID: PMC8308508.
Copy Download .nbib Format: NLM
Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats.

Molecular and cellular endocrinology

Yamada S, Ogura Y, Inoue K, Tanabe J, Sugaya T, Ohata K, Nagai Y, Natsuki Y, Hoshino S, Watanabe S, Ichikawa D, Kimura K, Shibagaki Y, Kamijo-Ikemori A.
PMID: 34606964
Mol Cell Endocrinol. 2022 Jan 01;539:111472. doi: 10.1016/j.mce.2021.111472. Epub 2021 Oct 01.

This study investigated the effect of liraglutide, a glucagon-like peptide-1 receptor agonist, on skeletal muscles in rats with type 2 diabetes. Male SDT fatty rats (8-week-old) were provided liraglutide, or insulin-hydralazine for 8 weeks; control SDT fatty rats and...

Cite
Yamada S, Ogura Y, Inoue K, et al. Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats. Mol Cell Endocrinol. 2021;539:111472doi: 10.1016/j.mce.2021.111472.
Yamada, S., Ogura, Y., Inoue, K., Tanabe, J., Sugaya, T., Ohata, K., Nagai, Y., Natsuki, Y., Hoshino, S., Watanabe, S., Ichikawa, D., Kimura, K., Shibagaki, Y., & Kamijo-Ikemori, A. (2022). Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats. Molecular and cellular endocrinology, 539111472. https://doi.org/10.1016/j.mce.2021.111472
Yamada, Shohei, et al. "Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats." Molecular and cellular endocrinology vol. 539 (2022): 111472. doi: https://doi.org/10.1016/j.mce.2021.111472
Yamada S, Ogura Y, Inoue K, Tanabe J, Sugaya T, Ohata K, Nagai Y, Natsuki Y, Hoshino S, Watanabe S, Ichikawa D, Kimura K, Shibagaki Y, Kamijo-Ikemori A. Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats. Mol Cell Endocrinol. 2022 Jan 01;539:111472. doi: 10.1016/j.mce.2021.111472. Epub 2021 Oct 01. PMID: 34606964.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 199 entries